Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of Ctx-8371 in Patients With Solid Tumors
Compass Therapeutics宣佈在針對實體瘤患者的Ctx-8371的1期研究中爲首位患者服用劑量
Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of Ctx-8371 in Patients With Solid Tumors
Compass Therapeutics宣佈在針對實體瘤患者的Ctx-8371的1期研究中爲首位患者服用劑量
使用瀏覽器的分享功能,分享給你的好友吧